Clinical Trial Update: Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases [Phase 1]

View source ↗

Summary

Phase 1 safety study of gene-modified donor T cell infusion after stem cell transplantation for non-malignant diseases has been terminated; results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemoglobinopathies
• Hemophagocytic Lymphohistiocytosis
• Immune Deficiency Disorders
• Inherited Bone Marrow Failure Syndrome
• Metabolic Disorders

Drugs mentioned

• Bellicum Pharmaceuticals gene-modified donor T-cells

Snippet

Sponsor: Bellicum Pharmaceuticals | Conditions: Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis | Phase 1 | Status: TERMINATED | Results posted: 2024-03-25